These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35351365)

  • 1. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
    Ren Z; Pineda FD; Howard FM; Hill E; Szasz T; Safi R; Medved M; Nanda R; Yankeelov TE; Abe H; Karczmar GS
    Acad Radiol; 2022 Oct; 29(10):1469-1479. PubMed ID: 35351365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
    Ren Z; Pineda FD; Howard FM; Fan X; Nanda R; Abe H; Kulkarni K; Karczmar GS
    Magn Reson Imaging; 2023 Dec; 104():9-15. PubMed ID: 37611646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density.
    Mori N; Abe H; Mugikura S; Takasawa C; Sato S; Miyashita M; Mori Y; Pineda FD; Karczmar GS; Tamura H; Takahashi S; Takase K
    Acad Radiol; 2019 Jul; 26(7):e141-e149. PubMed ID: 30269956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation between subcentimeter carcinomas and benign lesions using kinetic parameters derived from ultrafast dynamic contrast-enhanced breast MRI.
    Onishi N; Sadinski M; Gibbs P; Gallagher KM; Hughes MC; Ko ES; Dashevsky BZ; Shanbhag DD; Fung MM; Hunt TM; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Eur Radiol; 2020 Feb; 30(2):756-766. PubMed ID: 31468162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
    Wu S; Berg WA; Zuley ML; Kurland BF; Jankowitz RC; Nishikawa R; Gur D; Sumkin JH
    Breast Cancer Res; 2016 Jul; 18(1):76. PubMed ID: 27449059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrafast DCE-MRI for discriminating pregnancy-associated breast cancer lesions from lactation related background parenchymal enhancement.
    Nissan N; Anaby D; Mahameed G; Bauer E; Moss Massasa EE; Menes T; Agassi R; Brodsky A; Grimm R; Nickel MD; Roccia E; Sklair-Levy M
    Eur Radiol; 2023 Nov; 33(11):8122-8131. PubMed ID: 37278853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics Based on Dynamic Contrast-Enhanced MRI to Early Predict Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Therapy.
    Zeng Q; Ke M; Zhong L; Zhou Y; Zhu X; He C; Liu L
    Acad Radiol; 2023 Aug; 30(8):1638-1647. PubMed ID: 36564256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinicopathological-imaging nomogram for the prediction of pathological complete response in breast cancer cases administered neoadjuvant therapy.
    Yang W; Yang Y; Zhang C; Yin Q; Zhang N
    Magn Reson Imaging; 2024 Sep; 111():120-130. PubMed ID: 38703971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
    Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
    Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.
    Virostko J; Kuketz G; Higgins E; Wu C; Sorace AG; DiCarlo JC; Avery S; Patt D; Goodgame B; Yankeelov TE
    Eur J Radiol; 2021 Mar; 136():109534. PubMed ID: 33454460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmass Enhancement Breast Lesions: Diagnostic Performance of Kinetic Assessment on Ultrafast and Standard Dynamic Contrast-Enhanced MRI in Comparison With Morphologic Evaluation.
    Mori N; Sheth D; Abe H
    AJR Am J Roentgenol; 2020 Aug; 215(2):511-518. PubMed ID: 32452698
    [No Abstract]   [Full Text] [Related]  

  • 12. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
    Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
    Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI.
    Cao Y; Wang X; Li L; Shi J; Zeng X; Huang Y; Chen H; Jiang F; Yin T; Nickel D; Zhang J
    Diagn Interv Imaging; 2023 Dec; 104(12):605-614. PubMed ID: 37543490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer.
    Zeng Q; Xiong F; Liu L; Zhong L; Cai F; Zeng X
    Acad Radiol; 2023 Sep; 30 Suppl 2():S38-S49. PubMed ID: 37169624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
    Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
    Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement.
    Kim SY; Cho N; Choi Y; Shin SU; Kim ES; Lee SH; Chang JM; Moon WK
    Korean J Radiol; 2020 May; 21(5):561-571. PubMed ID: 32323501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    Bernardi D; Vatteroni G; Acquaviva A; Valentini M; Sabatino V; Bolengo I; Pellegrini M; Fantò C; Trimboli RM
    AJR Am J Roentgenol; 2022 Dec; 219(6):884-894. PubMed ID: 35731101
    [No Abstract]   [Full Text] [Related]  

  • 20. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
    Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
    Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.